VOLITIONRX LTD
Price data unavailable
Track VNRX in your trading journalAbout VOLITIONRX LTD
VOLITIONRX LTD (VNRX) is a publicly listed company on US equity markets.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.
The company reports trailing twelve-month revenue of $985,076 and net loss of $6.66M.
Key metrics include a return on equity of 20.8%, a debt-to-equity ratio of -1.33.
Use FINOTAUR to track VNRX's price action, review fundamentals, and stay current with company news — all in one research dashboard.
Fundamentals
| Revenue (TTM) | $985,076 |
| Net Income (TTM) | $-6.66M |
| EPS (TTM) | — |
| P/E Ratio | — |
| Return on Equity | 20.84% |
| Debt-to-Equity | -1.33 |
| Dividend per Share | — |
Recent News
- Benzinga·May 27
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
- Benzinga·Jan 3
Why Trinity Place Holdings Shares Are Trading Higher By 80%; Here Are 20 Stocks Moving Premarket
- Benzinga·Nov 27
IO Biotech And 2 Other Stocks Under $2 Insiders Are Buying
Want real-time analysis on VNRX?
Track it free in your trading journal. Log trades, tag setups, and review your edge.